#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Deficient	_
1-2	10-21	Functioning	_
1-3	22-24	of	_
1-4	25-40	Fronto-Striatal	_
1-5	41-49	Circuits	_
1-6	50-56	During	_
1-7	57-60	the	_
1-8	61-71	Resolution	_
1-9	72-74	of	_
1-10	75-84	Cognitive	_
1-11	85-93	Conflict	_
1-12	94-96	in	_
1-13	97-111	Cannabis-Using	http://maven.renci.org/NeuroBridge/neurobridge#StudyObjective
1-14	112-117	Youth	http://maven.renci.org/NeuroBridge/neurobridge#StudyObjective
1-15	118-127	Objective	http://maven.renci.org/NeuroBridge/neurobridge#StudyObjective
1-16	128-129	:	_
1-17	130-142	Disturbances	_
1-18	143-145	in	_
1-19	146-161	self-regulatory	_
1-20	162-169	control	_
1-21	170-173	are	_
1-22	174-182	involved	_
1-23	183-185	in	_
1-24	186-189	the	_
1-25	190-200	initiation	_
1-26	201-204	and	_
1-27	205-216	maintenance	_
1-28	217-219	of	_
1-29	220-229	addiction	_
1-30	230-231	,	_
1-31	232-241	including	_
1-32	242-250	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-33	251-254	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-34	255-263	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-35	264-265	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-36	266-269	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-37	270-271	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-38	272-273	.	_

2-1	274-276	In	_
2-2	277-283	adults	_
2-3	284-285	,	_
2-4	286-293	chronic	_
2-5	294-302	cannabis	_
2-6	303-306	use	_
2-7	307-309	is	_
2-8	310-320	associated	_
2-9	321-325	with	_
2-10	326-338	disturbances	_
2-11	339-341	in	_
2-12	342-357	fronto-striatal	_
2-13	358-366	circuits	_
2-14	367-373	during	_
2-15	374-379	tasks	_
2-16	380-384	that	_
2-17	385-392	require	_
2-18	393-396	the	_
2-19	397-407	engagement	_
2-20	408-410	of	_
2-21	411-426	self-regulatory	_
2-22	427-434	control	_
2-23	435-436	,	_
2-24	437-446	including	_
2-25	447-450	the	_
2-26	451-461	resolution	_
2-27	462-464	of	_
2-28	465-474	cognitive	_
2-29	475-483	conflict	_
2-30	484-485	.	_

3-1	486-498	Understudied	_
3-2	499-502	are	_
3-3	503-506	the	_
3-4	507-517	behavioral	_
3-5	518-521	and	_
3-6	522-528	neural	_
3-7	529-539	correlates	_
3-8	540-542	of	_
3-9	543-548	these	_
3-10	549-558	processes	_
3-11	559-566	earlier	_
3-12	567-569	in	_
3-13	570-573	the	_
3-14	574-580	course	_
3-15	581-583	of	_
3-16	584-592	cannabis	_
3-17	593-596	use	_
3-18	597-598	,	_
3-19	599-611	disentangled	_
3-20	612-616	from	_
3-21	617-624	effects	_
3-22	625-627	of	_
3-23	628-637	long-term	_
3-24	638-641	use	_
3-25	642-643	.	_

4-1	644-647	The	_
4-2	648-655	present	_
4-3	656-661	study	_
4-4	662-674	investigates	_
4-5	675-678	the	_
4-6	679-690	functioning	_
4-7	691-693	of	_
4-8	694-709	fronto-striatal	_
4-9	710-718	circuits	_
4-10	719-725	during	_
4-11	726-729	the	_
4-12	730-740	resolution	_
4-13	741-743	of	_
4-14	744-753	cognitive	_
4-15	754-762	conflict	_
4-16	763-765	in	_
4-17	766-780	cannabis-using	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
4-18	781-786	youth	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
4-19	787-788	.	_

5-1	789-795	Method	_
5-2	796-797	:	_
5-3	798-808	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-4	809-817	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	818-827	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	828-835	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-7	836-840	data	_
5-8	841-844	was	_
5-9	845-853	acquired	_
5-10	854-858	from	_
5-11	859-861	28	_
5-12	862-876	cannabis-using	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-13	877-878	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-14	879-881	CU	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-15	882-883	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-16	884-889	youth	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-17	890-893	and	_
5-18	894-896	32	_
5-19	897-908	age-matched	http://maven.renci.org/NeuroBridge/neurobridge#Age
5-20	909-916	healthy	http://maven.renci.org/NeuroBridge/neurobridge#AlternativeHealthyEatingIndex2010
5-21	917-929	participants	http://maven.renci.org/NeuroBridge/neurobridge#AlternativeHealthyEatingIndex2010
5-22	930-931	(	http://maven.renci.org/NeuroBridge/neurobridge#AlternativeHealthyEatingIndex2010
5-23	932-934	HC	http://maven.renci.org/NeuroBridge/neurobridge#AlternativeHealthyEatingIndex2010
5-24	935-936	)	http://maven.renci.org/NeuroBridge/neurobridge#AlternativeHealthyEatingIndex2010
5-25	937-943	during	_
5-26	944-947	the	_
5-27	948-959	performance	_
5-28	960-962	of	_
5-29	963-964	a	_
5-30	965-970	Simon	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
5-31	971-975	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
5-32	976-977	.	_

6-1	978-985	General	_
6-2	986-992	linear	_
6-3	993-1001	modeling	_
6-4	1002-1005	was	_
6-5	1006-1010	used	_
6-6	1011-1013	to	_
6-7	1014-1021	compare	_
6-8	1022-1030	patterns	_
6-9	1031-1033	of	_
6-10	1034-1039	brain	_
6-11	1040-1050	activation	_
6-12	1051-1057	during	_
6-13	1058-1065	correct	_
6-14	1066-1075	responses	_
6-15	1076-1078	to	_
6-16	1079-1087	conflict	_
6-17	1088-1095	stimuli	_
6-18	1096-1102	across	_
6-19	1103-1109	groups	_
6-20	1110-1111	.	_

7-1	1112-1131	Psychophysiological	_
7-2	1132-1143	interaction	_
7-3	1144-1152	analyses	_
7-4	1153-1157	were	_
7-5	1158-1162	used	_
7-6	1163-1165	to	_
7-7	1166-1173	examine	_
7-8	1174-1190	conflict-related	_
7-9	1191-1206	fronto-striatal	_
7-10	1207-1219	connectivity	_
7-11	1220-1226	across	_
7-12	1227-1233	groups	_
7-13	1234-1235	.	_

8-1	1236-1248	Associations	_
8-2	1249-1251	of	_
8-3	1252-1267	fronto-striatal	_
8-4	1268-1278	activation	_
8-5	1279-1282	and	_
8-6	1283-1295	connectivity	_
8-7	1296-1300	with	_
8-8	1301-1309	cannabis	_
8-9	1310-1313	use	_
8-10	1314-1322	measures	_
8-11	1323-1327	were	_
8-12	1328-1336	explored	_
8-13	1337-1338	.	_

9-1	1339-1346	Results	_
9-2	1347-1348	:	_
9-3	1349-1356	Reduced	_
9-4	1357-1373	conflict-related	_
9-5	1374-1382	activity	_
9-6	1383-1386	was	_
9-7	1387-1395	detected	_
9-8	1396-1398	in	_
9-9	1399-1401	CU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-10	1402-1410	relative	_
9-11	1411-1413	to	_
9-12	1414-1416	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-13	1417-1422	youth	_
9-14	1423-1425	in	_
9-15	1426-1441	fronto-striatal	_
9-16	1442-1449	regions	_
9-17	1450-1451	,	_
9-18	1452-1461	including	_
9-19	1462-1474	ventromedial	_
9-20	1475-1485	prefrontal	_
9-21	1486-1492	cortex	_
9-22	1493-1494	(	_
9-23	1495-1500	vmPFC	_
9-24	1501-1502	)	_
9-25	1503-1504	,	_
9-26	1505-1513	striatum	_
9-27	1514-1515	,	_
9-28	1516-1524	pallidum	_
9-29	1525-1528	and	_
9-30	1529-1537	thalamus	_
9-31	1538-1539	.	_

10-1	1540-1555	Fronto-striatal	_
10-2	1556-1568	connectivity	_
10-3	1569-1572	did	_
10-4	1573-1576	not	_
10-5	1577-1583	differ	_
10-6	1584-1590	across	_
10-7	1591-1597	groups	_
10-8	1598-1599	,	_
10-9	1600-1603	but	_
10-10	1604-1612	negative	_
10-11	1613-1625	connectivity	_
10-12	1626-1633	between	_
10-13	1634-1639	vmPFC	_
10-14	1640-1643	and	_
10-15	1644-1652	striatum	_
10-16	1653-1656	was	_
10-17	1657-1665	detected	_
10-18	1666-1668	in	_
10-19	1669-1673	both	_
10-20	1674-1680	groups	_
10-21	1681-1682	.	_

11-1	1683-1693	Conclusion	_
11-2	1694-1695	:	_
11-3	1696-1701	These	_
11-4	1702-1710	findings	_
11-5	1711-1714	are	_
11-6	1715-1725	consistent	_
11-7	1726-1730	with	_
11-8	1731-1739	previous	_
11-9	1740-1747	reports	_
11-10	1748-1750	of	_
11-11	1751-1770	cannabis-associated	_
11-12	1771-1783	disturbances	_
11-13	1784-1786	in	_
11-14	1787-1802	fronto-striatal	_
11-15	1803-1811	circuits	_
11-16	1812-1814	in	_
11-17	1815-1821	adults	_
11-18	1822-1825	and	_
11-19	1826-1831	point	_
11-20	1832-1834	to	_
11-21	1835-1838	the	_
11-22	1839-1847	specific	_
11-23	1848-1857	influence	_
11-24	1858-1860	of	_
11-25	1861-1869	cannabis	_
11-26	1870-1872	on	_
11-27	1873-1891	neurodevelopmental	_
11-28	1892-1899	changes	_
11-29	1900-1902	in	_
11-30	1903-1908	youth	_
11-31	1909-1910	.	_

12-1	1911-1917	Future	_
12-2	1918-1925	studies	_
12-3	1926-1932	should	_
12-4	1933-1940	examine	_
12-5	1941-1948	whether	_
12-6	1949-1964	fronto-striatal	_
12-7	1965-1976	functioning	_
12-8	1977-1979	is	_
12-9	1980-1981	a	_
12-10	1982-1990	reliable	_
12-11	1991-1997	marker	_
12-12	1998-2000	of	_
12-13	2001-2004	CUD	_
12-14	2005-2013	severity	_
12-15	2014-2017	and	_
12-16	2018-2027	potential	_
12-17	2028-2034	target	_
12-18	2035-2038	for	_
12-19	2039-2052	circuit-based	_
12-20	2053-2066	interventions	_
12-21	2067-2068	.	_

13-1	2069-2075	METHOD	http://maven.renci.org/NeuroBridge/neurobridge#DataAnalysisMethod
13-2	2076-2088	Participants	_
13-3	2089-2101	Participants	_
13-4	2102-2106	were	_
13-5	2107-2109	28	_
13-6	2110-2121	adolescents	_
13-7	2122-2125	and	_
13-8	2126-2134	emerging	_
13-9	2135-2141	adults	_
13-10	2142-2146	with	_
13-11	2147-2158	significant	_
13-12	2159-2167	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
13-13	2168-2171	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
13-14	2172-2173	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
13-15	2174-2176	CU	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
13-16	2177-2178	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
13-17	2179-2182	and	_
13-18	2183-2185	32	_
13-19	2186-2193	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-20	2194-2202	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-21	2203-2204	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-22	2205-2207	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-23	2208-2209	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
13-24	2210-2211	,	_
13-25	2212-2216	aged	_
13-26	2217-2222	14–23	_
13-27	2223-2228	years	_
13-28	2229-2230	,	_
13-29	2231-2236	group	_
13-30	2237-2244	matched	_
13-31	2245-2247	on	_
13-32	2248-2251	age	_
13-33	2252-2253	,	_
13-34	2254-2260	gender	_
13-35	2261-2262	,	_
13-36	2263-2276	socioeconomic	_
13-37	2277-2283	status	_
13-38	2284-2285	(	_
13-39	2286-2289	SES	_
13-40	2290-2291	)	_
13-41	2292-2293	,	_
13-42	2294-2298	race	_
13-43	2299-2302	and	_
13-44	2303-2312	ethnicity	_
13-45	2313-2314	.	_

14-1	2315-2327	Demographics	_
14-2	2328-2331	for	_
14-3	2332-2335	all	_
14-4	2336-2348	participants	_
14-5	2349-2352	and	_
14-6	2353-2361	clinical	_
14-7	2362-2369	ratings	_
14-8	2370-2373	for	_
14-9	2374-2377	the	_
14-10	2378-2380	CU	_
14-11	2381-2386	group	_
14-12	2387-2390	are	_
14-13	2391-2396	shown	_
14-14	2397-2399	in	_
14-15	2400-2405	Table	_
14-16	2406-2407	1	_
14-17	2408-2409	.	_

15-1	2410-2422	Participants	_
15-2	2423-2427	were	_
15-3	2428-2437	recruited	_
15-4	2438-2445	through	_
15-5	2446-2452	flyers	_
15-6	2453-2454	,	_
15-7	2455-2463	Internet	_
15-8	2464-2478	advertisements	_
15-9	2479-2480	,	_
15-10	2481-2494	word-of-mouth	_
15-11	2495-2496	,	_
15-12	2497-2500	and	_
15-13	2501-2506	local	_
15-14	2507-2513	mental	_
15-15	2514-2520	health	_
15-16	2521-2528	clinics	_
15-17	2529-2532	and	_
15-18	2533-2540	schools	_
15-19	2541-2542	.	_

16-1	2543-2547	This	_
16-2	2548-2553	study	_
16-3	2554-2559	aimed	_
16-4	2560-2562	to	_
16-5	2563-2569	assess	_
16-6	2570-2573	the	_
16-7	2574-2585	functioning	_
16-8	2586-2588	of	_
16-9	2589-2604	fronto-striatal	_
16-10	2605-2613	circuits	_
16-11	2614-2619	early	_
16-12	2620-2622	in	_
16-13	2623-2626	the	_
16-14	2627-2633	course	_
16-15	2634-2636	of	_
16-16	2637-2638	a	_
16-17	2639-2650	problematic	_
16-18	2651-2659	cannabis	_
16-19	2660-2663	use	_
16-20	2664-2674	trajectory	_
16-21	2675-2676	.	_

17-1	2677-2680	DSM	_
17-2	2681-2691	diagnostic	_
17-3	2692-2700	criteria	_
17-4	2701-2707	poorly	_
17-5	2708-2715	capture	_
17-6	2716-2719	the	_
17-7	2720-2728	patterns	_
17-8	2729-2730	,	_
17-9	2731-2743	consequences	_
17-10	2744-2745	,	_
17-11	2746-2749	and	_
17-12	2750-2758	severity	_
17-13	2759-2761	of	_
17-14	2762-2770	cannabis	_
17-15	2771-2774	use	_
17-16	2775-2777	in	_
17-17	2778-2783	youth	_
17-18	2784-2787	and	_
17-19	2788-2793	teens	_
17-20	2794-2799	often	_
17-21	2800-2810	experience	_
17-22	2811-2821	impairment	_
17-23	2822-2829	without	_
17-24	2830-2837	meeting	_
17-25	2838-2846	criteria	_
17-26	2847-2850	for	_
17-27	2851-2857	DSM-IV	_
17-28	2858-2867	substance	_
17-29	2868-2884	abuse/dependence	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse
17-30	2885-2887	or	_
17-31	2888-2889	a	_
17-32	2890-2895	DSM-5	_
17-33	2896-2899	SUD	_
17-34	2900-2901	.	_

18-1	2902-2906	Thus	_
18-2	2907-2908	,	_
18-3	2909-2918	inclusion	_
18-4	2919-2921	in	_
18-5	2922-2925	the	_
18-6	2926-2928	CU	_
18-7	2929-2934	group	_
18-8	2935-2943	required	_
18-9	2944-2951	meeting	_
18-10	2952-2954	at	_
18-11	2955-2960	least	_
18-12	2961-2964	one	_
18-13	2965-2971	DSM-IV	_
18-14	2972-2982	diagnostic	_
18-15	2983-2992	criterion	_
18-16	2993-2994	.	_

19-1	2995-3002	Because	_
19-2	3003-3005	it	_
19-3	3006-3008	is	_
19-4	3009-3017	possible	_
19-5	3018-3022	that	_
19-6	3023-3033	infrequent	_
19-7	3034-3042	cannabis	_
19-8	3043-3046	use	_
19-9	3047-3050	may	_
19-10	3051-3054	not	_
19-11	3055-3057	be	_
19-12	3058-3068	associated	_
19-13	3069-3073	with	_
19-14	3074-3080	neural	_
19-15	3081-3088	changes	_
19-16	3089-3090	,	_
19-17	3091-3100	inclusion	_
19-18	3101-3103	in	_
19-19	3104-3107	the	_
19-20	3108-3110	CU	_
19-21	3111-3116	group	_
19-22	3117-3125	required	_
19-23	3126-3127	“	_
19-24	3128-3136	moderate	_
19-25	3137-3138	”	_
19-26	3139-3142	use	_
19-27	3143-3150	defined	_
19-28	3151-3153	as	_
19-29	3154-3156	at	_
19-30	3157-3162	least	_
19-31	3163-3168	twice	_
19-32	3169-3175	weekly	_
19-33	3176-3177	.	_

20-1	3178-3180	CU	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
20-2	3181-3193	participants	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
20-3	3194-3198	were	_
20-4	3199-3207	excluded	_
20-5	3208-3210	if	_
20-6	3211-3215	they	_
20-7	3216-3219	had	_
20-8	3220-3221	a	_
20-9	3222-3230	lifetime	_
20-10	3231-3240	diagnosis	_
20-11	3241-3243	of	_
20-12	3244-3247	SUD	_
20-13	3248-3249	(	_
20-14	3250-3260	dependence	_
20-15	3261-3263	or	_
20-16	3264-3269	abuse	_
20-17	3270-3271	)	_
20-18	3272-3277	other	_
20-19	3278-3282	than	_
20-20	3283-3291	cannabis	_
20-21	3292-3294	or	_
20-22	3295-3297	if	_
20-23	3298-3301	any	_
20-24	3302-3311	substance	_
20-25	3312-3317	other	_
20-26	3318-3322	than	_
20-27	3323-3331	cannabis	_
20-28	3332-3333	(	_
20-29	3334-3337	THC	_
20-30	3338-3339	)	_
20-31	3340-3343	was	_
20-32	3344-3352	detected	_
20-33	3353-3355	by	_
20-34	3356-3357	a	_
20-35	3358-3363	urine	_
20-36	3364-3368	drug	_
20-37	3369-3373	test	_
20-38	3374-3375	(	_
20-39	3376-3388	Construction	_
20-40	3389-3396	12-Drug	_
20-41	3397-3403	Screen	_
20-42	3404-3408	Test	_
20-43	3409-3410	,	_
20-44	3411-3420	Innovacon	_
20-45	3421-3422	,	_
20-46	3423-3427	Inc.	_
20-47	3428-3429	,	_
20-48	3430-3433	San	_
20-49	3434-3439	Diego	_
20-50	3440-3441	,	_
20-51	3442-3444	CA	_
20-52	3445-3446	)	_
20-53	3447-3459	administered	_
20-54	3460-3462	on	_
20-55	3463-3466	the	_
20-56	3467-3470	day	_
20-57	3471-3473	of	_
20-58	3474-3477	the	_
20-59	3478-3482	scan	_
20-60	3483-3484	.	_

21-1	3485-3487	In	_
21-2	3488-3496	addition	_
21-3	3497-3498	,	_
21-4	3499-3501	CU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-5	3502-3514	participants	_
21-6	3515-3519	were	_
21-7	3520-3525	asked	_
21-8	3526-3528	to	_
21-9	3529-3536	abstain	_
21-10	3537-3539	at	_
21-11	3540-3545	least	_
21-12	3546-3548	12	_
21-13	3549-3554	hours	_
21-14	3555-3560	prior	_
21-15	3561-3563	to	_
21-16	3564-3583	assessment/scanning	_
21-17	3584-3585	.	_

22-1	3586-3588	It	_
22-2	3589-3595	should	_
22-3	3596-3598	be	_
22-4	3599-3604	noted	_
22-5	3605-3606	,	_
22-6	3607-3614	however	_
22-7	3615-3616	,	_
22-8	3617-3621	that	_
22-9	3622-3627	urine	_
22-10	3628-3632	drug	_
22-11	3633-3640	testing	_
22-12	3641-3644	was	_
22-13	3645-3648	not	_
22-14	3649-3653	used	_
22-15	3654-3656	to	_
22-16	3657-3666	determine	_
22-17	3667-3675	cannabis	_
22-18	3676-3679	use	_
22-19	3680-3690	abstinence	_
22-20	3691-3696	prior	_
22-21	3697-3699	to	_
22-22	3700-3708	scanning	_
22-23	3709-3716	because	_
22-24	3717-3720	THC	_
22-25	3721-3724	can	_
22-26	3725-3727	be	_
22-27	3728-3736	detected	_
22-28	3737-3739	in	_
22-29	3740-3745	urine	_
22-30	3746-3752	beyond	_
22-31	3753-3755	12	_
22-32	3756-3761	hours	_
22-33	3762-3767	after	_
22-34	3768-3771	use	_
22-35	3772-3773	.	_

23-1	3774-3776	HC	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
23-2	3777-3789	participants	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
23-3	3790-3793	did	_
23-4	3794-3797	not	_
23-5	3798-3802	meet	_
23-6	3803-3809	DSM-IV	_
23-7	3810-3818	criteria	_
23-8	3819-3822	for	_
23-9	3823-3826	any	_
23-10	3827-3830	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
23-11	3831-3834	and	_
23-12	3835-3838	had	_
23-13	3839-3841	no	_
23-14	3842-3849	history	_
23-15	3850-3852	of	_
23-16	3853-3861	cannabis	_
23-17	3862-3865	use	_
23-18	3866-3867	.	_

24-1	3868-3876	Cannabis	_
24-2	3877-3880	use	_
24-3	3881-3884	and	_
24-4	3885-3888	DSM	_
24-5	3889-3897	criteria	_
24-6	3898-3901	for	_
24-7	3902-3918	cannabis-related	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
24-8	3919-3928	disorders	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
24-9	3929-3933	were	_
24-10	3934-3942	assessed	_
24-11	3943-3947	with	_
24-12	3948-3951	the	_
24-13	3952-3965	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-14	3966-3976	Adolescent	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-15	3977-3985	Severity	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-16	3986-3995	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-17	3996-3997	(	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-18	3998-4004	CASI-A	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-19	4005-4006	)	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
24-20	4007-4008	,	_
24-21	4009-4012	the	_
24-22	4013-4021	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#FollowupDataCollection
24-23	4022-4033	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#FollowupDataCollection
24-24	4034-4035	(	http://maven.renci.org/NeuroBridge/neurobridge#FollowupDataCollection
24-25	4036-4040	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#FollowupDataCollection
24-26	4041-4042	)	http://maven.renci.org/NeuroBridge/neurobridge#FollowupDataCollection
24-27	4043-4044	,	_
24-28	4045-4048	the	_
24-29	4049-4059	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-30	4060-4068	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-31	4069-4078	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-32	4079-4082	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-33	4083-4089	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-34	4090-4096	Axis-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-35	4097-4106	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-36	4107-4108	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-37	4109-4115	SCID-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-38	4116-4117	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-39	4118-4121	for	_
24-40	4122-4134	participants	_
24-41	4135-4137	18	_
24-42	4138-4143	years	_
24-43	4144-4147	and	_
24-44	4148-4153	older	_
24-45	4154-4155	,	_
24-46	4156-4159	and	_
24-47	4160-4163	the	_
24-48	4164-4179	Kiddie-Schedule	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-49	4180-4183	for	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-50	4184-4193	Affective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-51	4194-4203	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-52	4204-4207	and	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-53	4208-4229	Schizophrenia-Present	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-54	4230-4233	and	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-55	4234-4242	Lifetime	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-56	4243-4250	Version	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-57	4251-4252	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-58	4253-4262	K-SADS-PL	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-59	4263-4264	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
24-60	4265-4268	for	_
24-61	4269-4274	those	_
24-62	4275-4280	under	_
24-63	4281-4283	18	_
24-64	4284-4289	years	_
24-65	4290-4291	.	_

25-1	4292-4304	Participants	_
25-2	4305-4309	with	_
25-3	4310-4311	a	_
25-4	4312-4319	history	_
25-5	4320-4322	of	_
25-6	4323-4335	neurological	_
25-7	4336-4343	illness	_
25-8	4344-4345	,	_
25-9	4346-4350	past	_
25-10	4351-4359	seizures	_
25-11	4360-4361	,	_
25-12	4362-4366	head	_
25-13	4367-4373	trauma	_
25-14	4374-4378	with	_
25-15	4379-4383	loss	_
25-16	4384-4386	of	_
25-17	4387-4400	consciousness	_
25-18	4401-4402	,	_
25-19	4403-4409	mental	_
25-20	4410-4421	retardation	_
25-21	4422-4423	,	_
25-22	4424-4437	developmental	_
25-23	4438-4446	disorder	_
25-24	4447-4448	,	_
25-25	4449-4451	or	_
25-26	4452-4456	Axis	_
25-27	4457-4458	I	_
25-28	4459-4470	psychiatric	_
25-29	4471-4480	disorders	_
25-30	4481-4485	were	_
25-31	4486-4494	excluded	_
25-32	4495-4496	.	_

26-1	4497-4507	Depressive	http://maven.renci.org/NeuroBridge/neurobridge#DepressiveDisorder
26-2	4508-4509	,	http://maven.renci.org/NeuroBridge/neurobridge#DepressiveDisorder
26-3	4510-4517	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder
26-4	4518-4521	and	http://maven.renci.org/NeuroBridge/neurobridge#AnxietyDisorder
26-5	4522-4531	attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-6	4532-4539	deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-7	4540-4553	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-8	4554-4555	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-9	4556-4560	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-10	4561-4562	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
26-11	4563-4572	disorders	_
26-12	4573-4577	were	_
26-13	4578-4587	permitted	_
26-14	4588-4590	in	_
26-15	4591-4594	the	_
26-16	4595-4597	CU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
26-17	4598-4603	group	_
26-18	4604-4605	,	_
26-19	4606-4611	given	_
26-20	4612-4617	their	_
26-21	4618-4622	high	_
26-22	4623-4635	co-morbidity	_
26-23	4636-4640	with	_
26-24	4641-4649	moderate	_
26-25	4650-4652	to	_
26-26	4653-4658	heavy	_
26-27	4659-4667	cannabis	_
26-28	4668-4671	use	_
26-29	4672-4674	in	_
26-30	4675-4680	youth	_
26-31	4681-4682	.	_

27-1	4683-4686	The	_
27-2	4687-4695	presence	_
27-3	4696-4698	of	_
27-4	4699-4704	these	_
27-5	4705-4708	and	_
27-6	4709-4714	other	_
27-7	4715-4719	Axis	_
27-8	4720-4721	1	_
27-9	4722-4731	disorders	_
27-10	4732-4735	was	_
27-11	4736-4746	determined	_
27-12	4747-4752	based	_
27-13	4753-4755	on	_
27-14	4756-4759	the	_
27-15	4760-4766	SCID-I	_
27-16	4767-4769	or	_
27-17	4770-4779	K-SADS-PL	_
27-18	4780-4781	.	_

28-1	4782-4785	The	_
28-2	4786-4800	DuPaul-Barkley	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-3	4801-4818	Attention-Deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-4	4819-4832	Hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-5	4833-4841	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-6	4842-4848	Rating	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-7	4849-4854	Scale	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
28-8	4855-4865	quantified	_
28-9	4866-4874	symptoms	_
28-10	4875-4877	of	_
28-11	4878-4889	inattention	_
28-12	4890-4893	and	_
28-13	4894-4907	hyperactivity	_
28-14	4908-4909	.	_

29-1	4910-4920	Full-scale	_
29-2	4921-4924	IQs	_
29-3	4925-4929	were	_
29-4	4930-4939	estimated	_
29-5	4940-4945	using	_
29-6	4946-4949	the	_
29-7	4950-4958	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-8	4959-4970	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-9	4971-4976	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-10	4977-4979	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-11	4980-4992	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-12	4993-4994	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-13	4995-4999	WASI	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-14	5000-5001	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
29-15	5002-5003	,	_
29-16	5004-5007	and	_
29-17	5008-5011	SES	_
29-18	5012-5015	was	_
29-19	5016-5026	calculated	_
29-20	5027-5032	based	_
29-21	5033-5035	on	_
29-22	5036-5044	parental	_
29-23	5045-5053	academic	_
29-24	5054-5057	and	_
29-25	5058-5070	occupational	_
29-26	5071-5082	achievement	_
29-27	5083-5088	using	_
29-28	5089-5092	the	_
29-29	5093-5101	Modified	http://maven.renci.org/NeuroBridge/neurobridge#CoagulationFactorAssay
29-30	5102-5114	Hollingshead	http://maven.renci.org/NeuroBridge/neurobridge#CoagulationFactorAssay
29-31	5115-5123	4-Factor	http://maven.renci.org/NeuroBridge/neurobridge#CoagulationFactorAssay
29-32	5124-5129	Index	http://maven.renci.org/NeuroBridge/neurobridge#CoagulationFactorAssay
29-33	5130-5131	.	_

30-1	5132-5135	All	_
30-2	5136-5144	clinical	_
30-3	5145-5149	data	_
30-4	5150-5154	were	_
30-5	5155-5163	reviewed	_
30-6	5164-5167	and	_
30-7	5168-5177	confirmed	_
30-8	5178-5180	by	_
30-9	5181-5182	a	_
30-10	5183-5195	psychiatrist	_
30-11	5196-5199	who	_
30-12	5200-5204	also	_
30-13	5205-5214	conducted	_
30-14	5215-5223	clinical	_
30-15	5224-5234	interviews	_
30-16	5235-5238	for	_
30-17	5239-5242	all	_
30-18	5243-5255	participants	_
30-19	5256-5257	.	_

31-1	5258-5263	Adult	_
31-2	5264-5276	participants	_
31-3	5277-5285	provided	_
31-4	5286-5294	informed	_
31-5	5295-5302	consent	_
31-6	5303-5304	.	_

32-1	5305-5310	Minor	_
32-2	5311-5323	participants	_
32-3	5324-5332	provided	_
32-4	5333-5339	assent	_
32-5	5340-5341	,	_
32-6	5342-5345	and	_
32-7	5346-5351	their	_
32-8	5352-5362	caregivers	_
32-9	5363-5371	provided	_
32-10	5372-5379	consent	_
32-11	5380-5381	.	_

33-1	5382-5385	The	_
33-2	5386-5394	research	_
33-3	5395-5403	protocol	_
33-4	5404-5407	was	_
33-5	5408-5416	approved	_
33-6	5417-5419	by	_
33-7	5420-5423	the	_
33-8	5424-5437	Institutional	_
33-9	5438-5444	Review	_
33-10	5445-5450	Board	_
33-11	5451-5453	of	_
33-12	5454-5457	the	_
33-13	5458-5461	New	_
33-14	5462-5466	York	_
33-15	5467-5472	State	_
33-16	5473-5484	Psychiatric	_
33-17	5485-5494	Institute	_
33-18	5495-5496	.	_

34-1	5497-5501	FMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
34-2	5502-5510	Paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
34-3	5511-5523	Participants	_
34-4	5524-5533	completed	_
34-5	5534-5537	the	_
34-6	5538-5543	Simon	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
34-7	5544-5548	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
34-8	5549-5550	(	_
34-9	5551-5561	previously	_
34-10	5562-5571	described	_
34-11	5572-5573	)	_
34-12	5574-5575	.	_

35-1	5576-5583	Briefly	_
35-2	5584-5585	,	_
35-3	5586-5598	participants	_
35-4	5599-5603	were	_
35-5	5604-5613	presented	_
35-6	5614-5618	with	_
35-7	5619-5620	a	_
35-8	5621-5629	leftward	_
35-9	5630-5632	or	_
35-10	5633-5642	rightward	_
35-11	5643-5651	pointing	_
35-12	5652-5657	arrow	_
35-13	5658-5660	on	_
35-14	5661-5665	each	_
35-15	5666-5671	trial	_
35-16	5672-5676	that	_
35-17	5677-5680	was	_
35-18	5681-5687	either	_
35-19	5688-5697	congruent	_
35-20	5698-5700	or	_
35-21	5701-5712	incongruent	_
35-22	5713-5717	with	_
35-23	5718-5721	its	_
35-24	5722-5730	position	_
35-25	5731-5732	(	_
35-26	5733-5737	left	_
35-27	5738-5740	or	_
35-28	5741-5746	right	_
35-29	5747-5748	)	_
35-30	5749-5751	on	_
35-31	5752-5755	the	_
35-32	5756-5762	screen	_
35-33	5763-5764	.	_

36-1	5765-5769	They	_
36-2	5770-5774	were	_
36-3	5775-5785	instructed	_
36-4	5786-5788	to	_
36-5	5789-5796	respond	_
36-6	5797-5799	as	_
36-7	5800-5807	quickly	_
36-8	5808-5811	and	_
36-9	5812-5822	accurately	_
36-10	5823-5825	as	_
36-11	5826-5834	possible	_
36-12	5835-5837	to	_
36-13	5838-5841	the	_
36-14	5842-5851	direction	_
36-15	5852-5854	of	_
36-16	5855-5858	the	_
36-17	5859-5864	arrow	_
36-18	5865-5867	by	_
36-19	5868-5876	pressing	_
36-20	5877-5878	a	_
36-21	5879-5885	button	_
36-22	5886-5888	on	_
36-23	5889-5890	a	_
36-24	5891-5899	response	_
36-25	5900-5903	box	_
36-26	5904-5909	using	_
36-27	5910-5913	the	_
36-28	5914-5919	index	_
36-29	5920-5926	finger	_
36-30	5927-5930	for	_
36-31	5931-5935	left	_
36-32	5936-5939	and	_
36-33	5940-5943	the	_
36-34	5944-5950	middle	_
36-35	5951-5957	finger	_
36-36	5958-5961	for	_
36-37	5962-5967	right	_
36-38	5968-5969	.	_

37-1	5970-5978	Stimulus	_
37-2	5979-5987	duration	_
37-3	5988-5991	was	_
37-4	5992-5996	1300	_
37-5	5997-5999	ms	_
37-6	6000-6001	,	_
37-7	6002-6006	with	_
37-8	6007-6015	jittered	_
37-9	6016-6025	intervals	_
37-10	6026-6033	ranging	_
37-11	6034-6038	from	_
37-12	6039-6043	4160	_
37-13	6044-6046	to	_
37-14	6047-6051	6960	_
37-15	6052-6054	ms	_
37-16	6055-6056	(	_
37-17	6057-6063	M=5350	_
37-18	6064-6065	,	_
37-19	6066-6076	SD=1159.98	_
37-20	6077-6078	)	_
37-21	6079-6086	between	_
37-22	6087-6091	each	_
37-23	6092-6097	trial	_
37-24	6098-6099	.	_

38-1	6100-6104	Each	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-2	6105-6107	of	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-3	6108-6109	3	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-4	6110-6114	runs	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-5	6115-6124	consisted	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-6	6125-6127	of	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-7	6128-6130	55	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-8	6131-6137	trials	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-9	6138-6139	,	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-10	6140-6144	with	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-11	6145-6147	11	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
38-12	6148-6153	blank	_
38-13	6154-6155	,	_
38-14	6156-6158	22	_
38-15	6159-6168	congruent	_
38-16	6169-6170	,	_
38-17	6171-6174	and	_
38-18	6175-6177	22	_
38-19	6178-6189	incongruent	_
38-20	6190-6197	stimuli	_
38-21	6198-6199	.	_

39-1	6200-6207	E-prime	_
39-2	6208-6216	software	_
39-3	6217-6218	(	_
39-4	6219-6229	Psychology	_
39-5	6230-6238	Software	_
39-6	6239-6244	Tools	_
39-7	6245-6246	,	_
39-8	6247-6251	Inc.	_
39-9	6252-6253	,	_
39-10	6254-6264	Sharpsburg	_
39-11	6265-6266	,	_
39-12	6267-6270	Pa.	_
39-13	6271-6272	)	_
39-14	6273-6276	was	_
39-15	6277-6281	used	_
39-16	6282-6284	to	_
39-17	6285-6292	program	_
39-18	6293-6296	and	_
39-19	6297-6300	run	_
39-20	6301-6304	the	_
39-21	6305-6315	experiment	_
39-22	6316-6319	and	_
39-23	6320-6322	to	_
39-24	6323-6329	record	_
39-25	6330-6342	participants	_
39-26	6343-6344	’	_
39-27	6345-6354	responses	_
39-28	6355-6358	and	_
39-29	6359-6367	reaction	_
39-30	6368-6373	times	_
39-31	6374-6375	(	_
39-32	6376-6379	RTs	_
39-33	6380-6381	)	_
39-34	6382-6383	.	_

40-1	6384-6394	Behavioral	_
40-2	6395-6403	Analyses	_
40-3	6404-6407	RTs	_
40-4	6408-6410	on	_
40-5	6411-6418	correct	_
40-6	6419-6425	trials	_
40-7	6426-6430	were	_
40-8	6431-6438	entered	_
40-9	6439-6441	as	_
40-10	6442-6451	dependent	_
40-11	6452-6461	variables	_
40-12	6462-6464	in	_
40-13	6465-6466	a	_
40-14	6467-6475	repeated	_
40-15	6476-6484	measures	_
40-16	6485-6486	,	_
40-17	6487-6498	mixed-model	_
40-18	6499-6504	ANOVA	_
40-19	6505-6507	in	_
40-20	6508-6511	IBM	_
40-21	6512-6516	SPSS	_
40-22	6517-6527	Statistics	_
40-23	6528-6532	22.0	_
40-24	6533-6534	(	_
40-25	6535-6541	Armonk	_
40-26	6542-6543	,	_
40-27	6544-6546	NY	_
40-28	6547-6548	:	_
40-29	6549-6552	IBM	_
40-30	6553-6558	Corp.	_
40-31	6559-6560	)	_
40-32	6561-6565	with	_
40-33	6566-6574	Stimulus	_
40-34	6575-6576	(	_
40-35	6577-6591	post-congruent	_
40-36	6592-6603	Incongruent	_
40-37	6604-6607	vs.	_
40-38	6608-6622	post-congruent	_
40-39	6623-6632	Congruent	_
40-40	6633-6634	)	_
40-41	6635-6637	as	_
40-42	6638-6641	the	_
40-43	6642-6656	within-subject	_
40-44	6657-6665	variable	_
40-45	6666-6669	and	_
40-46	6670-6675	group	_
40-47	6676-6677	(	_
40-48	6678-6680	CU	_
40-49	6681-6684	vs.	_
40-50	6685-6687	HC	_
40-51	6688-6689	)	_
40-52	6690-6692	as	_
40-53	6693-6696	the	_
40-54	6697-6712	between-subject	_
40-55	6713-6721	variable	_
40-56	6722-6723	.	_

41-1	6724-6729	Image	_
41-2	6730-6741	Acquisition	_
41-3	6742-6745	and	_
41-4	6746-6756	Processing	_
41-5	6757-6763	Images	_
41-6	6764-6768	were	_
41-7	6769-6778	collected	_
41-8	6779-6784	using	_
41-9	6785-6786	a	_
41-10	6787-6789	GE	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
41-11	6790-6795	Signa	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
41-12	6796-6797	3	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
41-13	6798-6803	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
41-14	6804-6806	LC	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
41-15	6807-6814	scanner	_
41-16	6815-6816	(	_
41-17	6817-6826	Milwaukee	_
41-18	6827-6828	,	_
41-19	6829-6831	WI	_
41-20	6832-6833	)	_
41-21	6834-6835	.	_

42-1	6836-6846	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
42-2	6847-6853	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
42-3	6854-6858	were	_
42-4	6859-6867	acquired	_
42-5	6868-6873	using	_
42-6	6874-6875	a	_
42-7	6876-6878	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-8	6879-6880	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-9	6881-6890	sensitive	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
42-10	6891-6892	,	_
42-11	6893-6910	gradient-recalled	_
42-12	6911-6912	,	_
42-13	6913-6919	single	_
42-14	6920-6924	shot	_
42-15	6925-6926	,	_
42-16	6927-6938	echo-planar	_
42-17	6939-6944	pulse	_
42-18	6945-6953	sequence	_
42-19	6954-6955	(	_
42-20	6956-6966	repetition	_
42-21	6967-6971	time	_
42-22	6972-6973	=	_
42-23	6974-6978	2200	_
42-24	6979-6981	ms	_
42-25	6982-6983	,	_
42-26	6984-6988	echo	_
42-27	6989-6993	time	_
42-28	6994-6995	=	_
42-29	6996-6998	30	_
42-30	6999-7001	ms	_
42-31	7002-7003	,	_
42-32	7004-7006	90	_
42-33	7007-7013	degree	_
42-34	7014-7018	flip	_
42-35	7019-7024	angle	_
42-36	7025-7026	,	_
42-37	7027-7033	single	_
42-38	7034-7044	excitation	_
42-39	7045-7048	per	_
42-40	7049-7054	image	_
42-41	7055-7056	,	_
42-42	7057-7059	24	_
42-43	7060-7061	*	_
42-44	7062-7064	24	_
42-45	7065-7067	cm	_
42-46	7068-7073	field	_
42-47	7074-7076	of	_
42-48	7077-7081	view	_
42-49	7082-7083	,	_
42-50	7084-7086	64	_
42-51	7087-7088	*	_
42-52	7089-7091	64	_
42-53	7092-7098	matrix	_
42-54	7099-7100	,	_
42-55	7101-7103	34	_
42-56	7104-7110	slices	_
42-57	7111-7116	3.5mm	_
42-58	7117-7122	thick	_
42-59	7123-7124	,	_
42-60	7125-7127	no	_
42-61	7128-7131	gap	_
42-62	7132-7133	,	_
42-63	7134-7142	covering	_
42-64	7143-7146	the	_
42-65	7147-7153	entire	_
42-66	7154-7159	brain	_
42-67	7160-7161	)	_
42-68	7162-7163	.	_

43-1	7164-7166	We	_
43-2	7167-7176	collected	_
43-3	7177-7180	140	_
43-4	7181-7192	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-5	7193-7200	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-6	7201-7202	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-7	7203-7206	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-8	7207-7208	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
43-9	7209-7216	volumes	_
43-10	7217-7220	for	_
43-11	7221-7225	each	_
43-12	7226-7229	run	_
43-13	7230-7231	.	_

44-1	7232-7237	Image	_
44-2	7238-7251	preprocessing	_
44-3	7252-7255	and	_
44-4	7256-7267	first-level	_
44-5	7268-7276	analyses	_
44-6	7277-7281	were	_
44-7	7282-7289	carried	_
44-8	7290-7293	out	_
44-9	7294-7299	using	_
44-10	7300-7305	SPM12	_
44-11	7306-7307	(	_
44-12	7308-7312	http	_
44-13	7313-7314	:	_
44-14	7315-7343	//www.fil.ion.ucl.ac.uk/spm/	_
44-15	7344-7345	)	_
44-16	7346-7349	and	_
44-17	7350-7356	MATLAB	_
44-18	7357-7360	9.0	_
44-19	7361-7362	(	_
44-20	7363-7372	Mathworks	_
44-21	7373-7374	,	_
44-22	7375-7381	Natick	_
44-23	7382-7383	,	_
44-24	7384-7386	MA	_
44-25	7387-7388	)	_
44-26	7389-7390	.	_

45-1	7391-7401	Functional	_
45-2	7402-7408	images	_
45-3	7409-7413	were	_
45-4	7414-7423	corrected	_
45-5	7424-7427	for	_
45-6	7428-7439	differences	_
45-7	7440-7442	in	_
45-8	7443-7448	slice	_
45-9	7449-7455	timing	_
45-10	7456-7461	using	_
45-11	7462-7480	sinc-interpolation	_
45-12	7481-7482	,	_
45-13	7483-7486	and	_
45-14	7487-7491	head	_
45-15	7492-7500	movement	_
45-16	7501-7504	was	_
45-17	7505-7514	corrected	_
45-18	7515-7520	using	_
45-19	7521-7522	a	_
45-20	7523-7536	least-squares	_
45-21	7537-7545	approach	_
45-22	7546-7549	and	_
45-23	7550-7551	a	_
45-24	7552-7563	6-parameter	_
45-25	7564-7569	rigid	_
45-26	7570-7574	body	_
45-27	7575-7582	spatial	_
45-28	7583-7597	transformation	_
45-29	7598-7599	.	_

46-1	7600-7610	Structural	_
46-2	7611-7615	data	_
46-3	7616-7620	were	_
46-4	7621-7633	coregistered	_
46-5	7634-7636	to	_
46-6	7637-7640	the	_
46-7	7641-7651	functional	_
46-8	7652-7656	data	_
46-9	7657-7660	and	_
46-10	7661-7670	segmented	_
46-11	7671-7675	into	_
46-12	7676-7682	tissue	_
46-13	7683-7694	probability	_
46-14	7695-7699	maps	_
46-15	7700-7701	,	_
46-16	7702-7706	bias	_
46-17	7707-7716	corrected	_
46-18	7717-7720	and	_
46-19	7721-7730	spatially	_
46-20	7731-7741	normalized	_
46-21	7742-7744	to	_
46-22	7745-7748	the	_
46-23	7749-7757	Montreal	_
46-24	7758-7770	Neurological	_
46-25	7771-7780	Institute	_
46-26	7781-7782	(	_
46-27	7783-7786	MNI	_
46-28	7787-7788	)	_
46-29	7789-7794	space	_
46-30	7795-7797	of	_
46-31	7798-7799	1	_
46-32	7800-7801	×	_
46-33	7802-7803	1	_
46-34	7804-7805	×	_
46-35	7806-7807	1	_
46-36	7808-7811	mm3	_
46-37	7812-7818	voxels	_
46-38	7819-7820	.	_

47-1	7821-7826	Using	_
47-2	7827-7830	the	_
47-3	7831-7842	deformation	_
47-4	7843-7849	fields	_
47-5	7850-7852	of	_
47-6	7853-7858	these	_
47-7	7859-7868	segmented	_
47-8	7869-7875	images	_
47-9	7876-7877	,	_
47-10	7878-7881	the	_
47-11	7882-7892	functional	_
47-12	7893-7899	images	_
47-13	7900-7904	were	_
47-14	7905-7917	subsequently	_
47-15	7918-7927	spatially	_
47-16	7928-7938	normalized	_
47-17	7939-7941	to	_
47-18	7942-7945	MNI	_
47-19	7946-7951	space	_
47-20	7952-7954	of	_
47-21	7955-7958	and	_
47-22	7959-7960	3	_
47-23	7961-7962	×	_
47-24	7963-7964	3	_
47-25	7965-7966	×	_
47-26	7967-7968	3	_
47-27	7969-7972	mm3	_
47-28	7973-7979	voxels	_
47-29	7980-7981	.	_

48-1	7982-7984	An	_
48-2	7985-7989	8-mm	_
48-3	7990-8013	full-width/half-maximum	_
48-4	8014-8023	isotropic	_
48-5	8024-8032	Gaussian	_
48-6	8033-8042	smoothing	_
48-7	8043-8049	kernel	_
48-8	8050-8053	was	_
48-9	8054-8061	applied	_
48-10	8062-8064	to	_
48-11	8065-8068	all	_
48-12	8069-8079	normalized	_
48-13	8080-8090	functional	_
48-14	8091-8097	images	_
48-15	8098-8099	.	_

49-1	8100-8103	All	_
49-2	8104-8112	analyses	_
49-3	8113-8121	included	_
49-4	8122-8123	a	_
49-5	8124-8132	temporal	_
49-6	8133-8142	high-pass	_
49-7	8143-8149	filter	_
49-8	8150-8151	(	_
49-9	8152-8155	128	_
49-10	8156-8157	s	_
49-11	8158-8159	)	_
49-12	8160-8163	and	_
49-13	8164-8174	correction	_
49-14	8175-8178	for	_
49-15	8179-8187	temporal	_
49-16	8188-8203	autocorrelation	_
49-17	8204-8209	using	_
49-18	8210-8212	an	_
49-19	8213-8227	autoregressive	_
49-20	8228-8230	AR	_
49-21	8231-8232	(	_
49-22	8233-8234	1	_
49-23	8235-8236	)	_
49-24	8237-8242	model	_
49-25	8243-8244	.	_

50-1	8245-8249	Each	_
50-2	8250-8255	image	_
50-3	8256-8259	was	_
50-4	8260-8266	scaled	_
50-5	8267-8269	to	_
50-6	8270-8274	have	_
50-7	8275-8276	a	_
50-8	8277-8283	global	_
50-9	8284-8288	mean	_
50-10	8289-8298	intensity	_
50-11	8299-8301	of	_
50-12	8302-8305	100	_
50-13	8306-8307	.	_

51-1	8308-8311	For	_
51-2	8312-8316	each	_
51-3	8317-8328	participant	_
51-4	8329-8330	,	_
51-5	8331-8343	preprocessed	_
51-6	8344-8348	time	_
51-7	8349-8355	series	_
51-8	8356-8360	data	_
51-9	8361-8365	from	_
51-10	8366-8369	all	_
51-11	8370-8375	three	_
51-12	8376-8381	Simon	_
51-13	8382-8386	task	_
51-14	8387-8391	runs	_
51-15	8392-8393	(	_
51-16	8394-8397	420	_
51-17	8398-8405	volumes	_
51-18	8406-8407	)	_
51-19	8408-8412	were	_
51-20	8413-8420	modeled	_
51-21	8421-8426	using	_
51-22	8427-8428	a	_
51-23	8429-8436	General	_
51-24	8437-8443	Linear	_
51-25	8444-8449	Model	_
51-26	8450-8451	(	_
51-27	8452-8455	GLM	_
51-28	8456-8457	)	_
51-29	8458-8462	with	_
51-30	8463-8466	six	_
51-31	8467-8477	conditions	_
51-32	8478-8479	:	_
51-33	8480-8481	1	_
51-34	8482-8483	)	_
51-35	8484-8495	Incongruent	_
51-36	8496-8503	correct	_
51-37	8504-8510	trials	_
51-38	8511-8519	preceded	_
51-39	8520-8522	by	_
51-40	8523-8532	congruent	_
51-41	8533-8539	trials	_
51-42	8540-8541	(	_
51-43	8542-8544	cI	_
51-44	8545-8546	)	_
51-45	8547-8548	,	_
51-46	8549-8550	2	_
51-47	8551-8552	)	_
51-48	8553-8562	Congruent	_
51-49	8563-8570	correct	_
51-50	8571-8577	trials	_
51-51	8578-8586	preceded	_
51-52	8587-8589	by	_
51-53	8590-8601	incongruent	_
51-54	8602-8608	trials	_
51-55	8609-8610	(	_
51-56	8611-8613	iC	_
51-57	8614-8615	)	_
51-58	8616-8617	,	_
51-59	8618-8619	3	_
51-60	8620-8621	)	_
51-61	8622-8633	Incongruent	_
51-62	8634-8641	correct	_
51-63	8642-8648	trials	_
51-64	8649-8657	preceded	_
51-65	8658-8660	by	_
51-66	8661-8672	incongruent	_
51-67	8673-8679	trials	_
51-68	8680-8681	(	_
51-69	8682-8684	iI	_
51-70	8685-8686	)	_
51-71	8687-8688	,	_
51-72	8689-8690	4	_
51-73	8691-8692	)	_
51-74	8693-8702	Congruent	_
51-75	8703-8710	correct	_
51-76	8711-8717	trials	_
51-77	8718-8726	preceded	_
51-78	8727-8729	by	_
51-79	8730-8739	congruent	_
51-80	8740-8746	trials	_
51-81	8747-8748	(	_
51-82	8749-8751	cC	_
51-83	8752-8753	)	_
51-84	8754-8755	,	_
51-85	8756-8757	5	_
51-86	8758-8759	)	_
51-87	8760-8768	fixation	_
51-88	8769-8775	trials	_
51-89	8776-8777	,	_
51-90	8778-8781	and	_
51-91	8782-8783	6	_
51-92	8784-8785	)	_
51-93	8786-8795	incorrect	_
51-94	8796-8802	trials	_
51-95	8803-8804	(	_
51-96	8805-8816	incongruent	_
51-97	8817-8819	or	_
51-98	8820-8829	congruent	_
51-99	8830-8831	)	_
51-100	8832-8833	,	_
51-101	8834-8843	including	_
51-102	8844-8849	those	_
51-103	8850-8856	trials	_
51-104	8857-8861	with	_
51-105	8862-8865	RTs	_
51-106	8866-8871	below	_
51-107	8872-8875	the	_
51-108	8876-8883	minimum	_
51-109	8884-8886	RT	_
51-110	8887-8889	of	_
51-111	8890-8893	200	_
51-112	8894-8896	ms	_
51-113	8897-8905	required	_
51-114	8906-8909	for	_
51-115	8910-8918	stimulus	_
51-116	8919-8928	detection	_
51-117	8929-8932	and	_
51-118	8933-8943	processing	_
51-119	8944-8945	.	_

52-1	8946-8953	Because	_
52-2	8954-8956	of	_
52-3	8957-8960	the	_
52-4	8961-8968	limited	_
52-5	8969-8975	number	_
52-6	8976-8978	of	_
52-7	8979-8988	incorrect	_
52-8	8989-8995	trials	_
52-9	8996-8997	,	_
52-10	8998-9007	contrasts	_
52-11	9008-9017	involving	_
52-12	9018-9023	these	_
52-13	9024-9030	trials	_
52-14	9031-9035	were	_
52-15	9036-9039	not	_
52-16	9040-9048	assessed	_
52-17	9049-9050	.	_

53-1	9051-9054	All	_
53-2	9055-9057	of	_
53-3	9058-9061	the	_
53-4	9062-9066	task	_
53-5	9067-9077	regressors	_
53-6	9078-9082	were	_
53-7	9083-9092	convolved	_
53-8	9093-9097	with	_
53-9	9098-9101	the	_
53-10	9102-9111	canonical	_
53-11	9112-9115	HRF	_
53-12	9116-9117	,	_
53-13	9118-9121	and	_
53-14	9122-9135	least-squares	_
53-15	9136-9146	regression	_
53-16	9147-9150	was	_
53-17	9151-9155	used	_
53-18	9156-9158	to	_
53-19	9159-9167	estimate	_
53-20	9168-9178	parameters	_
53-21	9179-9182	for	_
53-22	9183-9187	each	_
53-23	9188-9199	independent	_
53-24	9200-9208	variable	_
53-25	9209-9212	for	_
53-26	9213-9217	each	_
53-27	9218-9229	participant	_
53-28	9230-9231	.	_

54-1	9232-9234	To	_
54-2	9235-9241	ensure	_
54-3	9242-9246	that	_
54-4	9247-9250	the	_
54-5	9251-9266	non-significant	_
54-6	9267-9273	motion	_
54-7	9274-9285	differences	_
54-8	9286-9291	could	_
54-9	9292-9295	not	_
54-10	9296-9303	account	_
54-11	9304-9307	for	_
54-12	9308-9311	our	_
54-13	9312-9319	results	_
54-14	9320-9321	,	_
54-15	9322-9324	we	_
54-16	9325-9333	included	_
54-17	9334-9336	24	_
54-18	9337-9345	nuisance	_
54-19	9346-9352	motion	_
54-20	9353-9363	regressors	_
54-21	9364-9366	as	_
54-22	9367-9377	covariates	_
54-23	9378-9380	of	_
54-24	9381-9393	non-interest	_
54-25	9394-9396	to	_
54-26	9397-9404	capture	_
54-27	9405-9411	linear	_
54-28	9412-9413	,	_
54-29	9414-9423	quadratic	_
54-30	9424-9425	,	_
54-31	9426-9438	differential	_
54-32	9439-9440	,	_
54-33	9441-9444	and	_
54-34	9445-9454	quadratic	_
54-35	9455-9467	differential	_
54-36	9468-9474	motion	_
54-37	9475-9476	.	_

55-1	9477-9481	Runs	_
55-2	9482-9484	in	_
55-3	9485-9490	which	_
55-4	9491-9492	a	_
55-5	9493-9504	participant	_
55-6	9505-9508	had	_
55-7	9509-9513	more	_
55-8	9514-9518	than	_
55-9	9519-9521	30	_
55-10	9522-9523	%	_
55-11	9524-9529	error	_
55-12	9530-9534	rate	_
55-13	9535-9536	(	_
55-14	9537-9539	ER	_
55-15	9540-9541	)	_
55-16	9542-9544	on	_
55-17	9545-9548	the	_
55-18	9549-9553	task	_
55-19	9554-9556	or	_
55-20	9557-9561	more	_
55-21	9562-9566	than	_
55-22	9567-9570	3mm	_
55-23	9571-9573	of	_
55-24	9574-9579	total	_
55-25	9580-9592	displacement	_
55-26	9593-9595	in	_
55-27	9596-9599	any	_
55-28	9600-9602	of	_
55-29	9603-9606	the	_
55-30	9607-9608	6	_
55-31	9609-9617	standard	_
55-32	9618-9624	motion	_
55-33	9625-9635	parameters	_
55-34	9636-9637	,	_
55-35	9638-9647	following	_
55-36	9648-9658	conversion	_
55-37	9659-9661	of	_
55-38	9662-9672	rotational	_
55-39	9673-9683	parameters	_
55-40	9684-9686	to	_
55-41	9687-9696	distances	_
55-42	9697-9699	by	_
55-43	9700-9709	computing	_
55-44	9710-9713	the	_
55-45	9714-9717	arc	_
55-46	9718-9724	length	_
55-47	9725-9737	displacement	_
55-48	9738-9740	on	_
55-49	9741-9744	the	_
55-50	9745-9752	surface	_
55-51	9753-9755	of	_
55-52	9756-9757	a	_
55-53	9758-9764	sphere	_
55-54	9765-9769	with	_
55-55	9770-9776	radius	_
55-56	9777-9779	50	_
55-57	9780-9782	mm	_
55-58	9783-9784	,	_
55-59	9785-9789	were	_
55-60	9790-9800	considered	_
55-61	9801-9805	poor	_
55-62	9806-9813	quality	_
55-63	9814-9818	data	_
55-64	9819-9822	and	_
55-65	9823-9831	excluded	_
55-66	9832-9836	from	_
55-67	9837-9840	our	_
55-68	9841-9849	analyses	_
55-69	9850-9851	.	_

56-1	9852-9868	Conflict-related	_
56-2	9869-9879	Activation	_
56-3	9880-9889	Parameter	_
56-4	9890-9899	estimates	_
56-5	9900-9908	averaged	_
56-6	9909-9915	across	_
56-7	9916-9919	the	_
56-8	9920-9921	3	_
56-9	9922-9926	runs	_
56-10	9927-9931	were	_
56-11	9932-9936	used	_
56-12	9937-9939	to	_
56-13	9940-9947	produce	_
56-14	9948-9950	an	_
56-15	9951-9962	incongruent	_
56-16	9963-9964	(	_
56-17	9965-9967	cI	_
56-18	9968-9971	and	_
56-19	9972-9974	cC	_
56-20	9975-9976	)	_
56-21	9977-9983	versus	_
56-22	9984-9993	congruent	_
56-23	9994-9995	(	_
56-24	9996-9998	cC	_
56-25	9999-10002	and	_
56-26	10003-10005	iC	_
56-27	10006-10007	)	_
56-28	10008-10016	contrast	_
56-29	10017-10018	(	_
56-30	10019-10022	I-C	_
56-31	10023-10024	)	_
56-32	10025-10028	for	_
56-33	10029-10033	each	_
56-34	10034-10045	participant	_
56-35	10046-10048	to	_
56-36	10049-10056	isolate	_
56-37	10057-10062	brain	_
56-38	10063-10073	activation	_
56-39	10074-10084	associated	_
56-40	10085-10089	with	_
56-41	10090-10093	the	_
56-42	10094-10104	engagement	_
56-43	10105-10107	of	_
56-44	10108-10123	self-regulatory	_
56-45	10124-10131	control	_
56-46	10132-10135	and	_
56-47	10136-10146	resolution	_
56-48	10147-10149	of	_
56-49	10150-10159	cognitive	_
56-50	10160-10168	conflict	_
56-51	10169-10170	(	_
56-52	10171-10175	i.e.	_
56-53	10176-10177	,	_
56-54	10178-10190	interference	_
56-55	10191-10197	effect	_
56-56	10198-10199	)	_
56-57	10200-10201	.	_

57-1	10202-10205	The	_
57-2	10206-10209	I-C	_
57-3	10210-10219	parameter	_
57-4	10220-10229	estimates	_
57-5	10230-10234	maps	_
57-6	10235-10239	were	_
57-7	10240-10248	compared	_
57-8	10249-10255	across	_
57-9	10256-10262	groups	_
57-10	10263-10265	in	_
57-11	10266-10267	a	_
57-12	10268-10280	second-level	_
57-13	10281-10284	GLM	_
57-14	10285-10294	adjusting	_
57-15	10295-10298	for	_
57-16	10299-10302	age	_
57-17	10303-10306	and	_
57-18	10307-10313	gender	_
57-19	10314-10315	,	_
57-20	10316-10321	using	_
57-21	10322-10325	the	_
57-22	10326-10336	two-sample	_
57-23	10337-10343	t-test	_
57-24	10344-10352	function	_
57-25	10353-10357	with	_
57-26	10358-10368	covariates	_
57-27	10369-10380	implemented	_
57-28	10381-10383	in	_
57-29	10384-10389	SPM12	_
57-30	10390-10391	.	_

58-1	10392-10393	A	_
58-2	10394-10404	voxel-wise	_
58-3	10405-10421	cluster-defining	_
58-4	10422-10431	threshold	_
58-5	10432-10433	(	_
58-6	10434-10437	CDT	_
58-7	10438-10439	)	_
58-8	10440-10442	of	_
58-9	10443-10444	p	_
58-10	10445-10446	<	_
58-11	10447-10451	.001	_
58-12	10452-10455	was	_
58-13	10456-10463	applied	_
58-14	10464-10475	whole-brain	_
58-15	10476-10477	,	_
58-16	10478-10481	and	_
58-17	10482-10489	minimum	_
58-18	10490-10497	cluster	_
58-19	10498-10504	extent	_
58-20	10505-10508	for	_
58-21	10509-10521	significance	_
58-22	10522-10524	at	_
58-23	10525-10526	a	_
58-24	10527-10533	Family	_
58-25	10534-10538	Wise	_
58-26	10539-10544	Error	_
58-27	10545-10546	(	_
58-28	10547-10550	FWE	_
58-29	10551-10552	)	_
58-30	10553-10557	rate	_
58-31	10558-10560	of	_
58-32	10561-10562	p	_
58-33	10563-10564	<	_
58-34	10565-10568	.05	_
58-35	10569-10572	was	_
58-36	10573-10583	determined	_
58-37	10584-10586	by	_
58-38	10587-10590	the	_
58-39	10591-10595	FWEc	_
58-40	10596-10609	cluster-level	_
58-41	10610-10620	correction	_
58-42	10621-10624	for	_
58-43	10625-10633	multiple	_
58-44	10634-10644	comparison	_
58-45	10645-10653	function	_
58-46	10654-10665	implemented	_
58-47	10666-10668	in	_
58-48	10669-10674	SPM12	_
58-49	10675-10676	.	_

59-1	10677-10693	Conflict-related	_
59-2	10694-10704	Functional	_
59-3	10705-10717	Connectivity	_
59-4	10718-10720	To	_
59-5	10721-10728	further	_
59-6	10729-10735	assess	_
59-7	10736-10739	the	_
59-8	10740-10751	functioning	_
59-9	10752-10754	of	_
59-10	10755-10770	fronto-striatal	_
59-11	10771-10779	circuits	_
59-12	10780-10788	involved	_
59-13	10789-10791	in	_
59-14	10792-10795	the	_
59-15	10796-10806	resolution	_
59-16	10807-10809	of	_
59-17	10810-10819	cognitive	_
59-18	10820-10828	conflict	_
59-19	10829-10831	in	_
59-20	10832-10834	CU	_
59-21	10835-10843	relative	_
59-22	10844-10846	to	_
59-23	10847-10849	HC	_
59-24	10850-10851	,	_
59-25	10852-10854	we	_
59-26	10855-10867	investigated	_
59-27	10868-10873	group	_
59-28	10874-10885	differences	_
59-29	10886-10888	in	_
59-30	10889-10905	conflict-related	_
59-31	10906-10916	functional	_
59-32	10917-10929	connectivity	_
59-33	10930-10931	.	_

60-1	10932-10934	To	_
60-2	10935-10937	do	_
60-3	10938-10940	so	_
60-4	10941-10942	,	_
60-5	10943-10945	we	_
60-6	10946-10954	computed	_
60-7	10955-10956	a	_
60-8	10957-10976	psychophysiological	_
60-9	10977-10988	interaction	_
60-10	10989-10990	(	_
60-11	10991-10994	PPI	_
60-12	10995-10996	)	_
60-13	10997-10999	of	_
60-14	11000-11003	the	_
60-15	11004-11018	trial-by-trial	_
60-16	11019-11031	psychometric	_
60-17	11032-11040	estimate	_
60-18	11041-11043	of	_
60-19	11044-11052	conflict	_
60-20	11053-11054	(	_
60-21	11055-11058	I-C	_
60-22	11059-11060	)	_
60-23	11061-11063	by	_
60-24	11064-11067	the	_
60-25	11068-11081	physiological	_
60-26	11082-11092	activation	_
60-27	11093-11099	during	_
60-28	11100-11103	I-C	_
60-29	11104-11110	trials	_
60-30	11111-11113	in	_
60-31	11114-11115	a	_
60-32	11116-11128	functionally	_
60-33	11129-11136	defined	_
60-34	11137-11144	frontal	_
60-35	11145-11149	seed	_
60-36	11150-11151	.	_

61-1	11152-11155	The	_
61-2	11156-11160	seed	_
61-3	11161-11164	was	_
61-4	11165-11172	defined	_
61-5	11173-11175	as	_
61-6	11176-11177	a	_
61-7	11178-11189	6-mm-radius	_
61-8	11190-11196	sphere	_
61-9	11197-11205	centered	_
61-10	11206-11208	on	_
61-11	11209-11212	the	_
61-12	11213-11224	coordinates	_
61-13	11225-11230	where	_
61-14	11231-11238	maximal	_
61-15	11239-11244	group	_
61-16	11245-11256	differences	_
61-17	11257-11259	in	_
61-18	11260-11263	I-C	_
61-19	11264-11274	activation	_
61-20	11275-11279	were	_
61-21	11280-11285	found	_
61-22	11286-11292	within	_
61-23	11293-11296	the	_
61-24	11297-11302	vmPFC	_
61-25	11303-11304	.	_

62-1	11305-11307	We	_
62-2	11308-11312	then	_
62-3	11313-11322	regressed	_
62-4	11323-11327	this	_
62-5	11328-11331	PPI	_
62-6	11332-11336	term	_
62-7	11337-11344	against	_
62-8	11345-11356	whole-brain	_
62-9	11357-11367	activation	_
62-10	11368-11372	maps	_
62-11	11373-11375	to	_
62-12	11376-11384	identify	_
62-13	11385-11392	regions	_
62-14	11393-11395	in	_
62-15	11396-11401	which	_
62-16	11402-11410	coupling	_
62-17	11411-11415	with	_
62-18	11416-11419	the	_
62-19	11420-11425	vmPFC	_
62-20	11426-11432	varied	_
62-21	11433-11435	as	_
62-22	11436-11437	a	_
62-23	11438-11446	function	_
62-24	11447-11449	of	_
62-25	11450-11458	conflict	_
62-26	11459-11460	(	_
62-27	11461-11464	I-C	_
62-28	11465-11466	)	_
62-29	11467-11468	.	_

63-1	11469-11477	Positive	_
63-2	11478-11481	and	_
63-3	11482-11490	negative	_
63-4	11491-11503	connectivity	_
63-5	11504-11507	are	_
63-6	11508-11520	respectively	_
63-7	11521-11528	defined	_
63-8	11529-11531	as	_
63-9	11532-11543	significant	_
63-10	11544-11552	positive	_
63-11	11553-11556	and	_
63-12	11557-11565	negative	_
63-13	11566-11578	correlations	_
63-14	11579-11586	between	_
63-15	11587-11594	regions	_
63-16	11595-11596	’	_
63-17	11597-11607	timeseries	_
63-18	11608-11609	.	_

64-1	11610-11617	Regions	_
64-2	11618-11620	in	_
64-3	11621-11626	which	_
64-4	11627-11637	timeseries	_
64-5	11638-11641	are	_
64-6	11642-11654	uncorrelated	_
64-7	11655-11658	are	_
64-8	11659-11669	considered	_
64-9	11670-11681	unconnected	_
64-10	11682-11683	.	_

65-1	11684-11685	A	_
65-2	11686-11698	second-level	_
65-3	11699-11707	analysis	_
65-4	11708-11711	was	_
65-5	11712-11721	conducted	_
65-6	11722-11724	to	_
65-7	11725-11729	test	_
65-8	11730-11735	group	_
65-9	11736-11747	differences	_
65-10	11748-11750	in	_
65-11	11751-11767	conflict-related	_
65-12	11768-11778	functional	_
65-13	11779-11791	connectivity	_
65-14	11792-11793	,	_
65-15	11794-11803	adjusting	_
65-16	11804-11807	for	_
65-17	11808-11811	age	_
65-18	11812-11815	and	_
65-19	11816-11822	gender	_
65-20	11823-11824	.	_

66-1	11825-11832	Because	_
66-2	11833-11835	of	_
66-3	11836-11839	our	_
66-4	11840-11841	a	_
66-5	11842-11848	priori	_
66-6	11849-11859	hypotheses	_
66-7	11860-11862	of	_
66-8	11863-11878	fronto-striatal	_
66-9	11879-11891	disturbances	_
66-10	11892-11893	,	_
66-11	11894-11899	these	_
66-12	11900-11911	group-level	_
66-13	11912-11920	analyses	_
66-14	11921-11923	of	_
66-15	11924-11936	connectivity	_
66-16	11937-11941	with	_
66-17	11942-11947	vmPFC	_
66-18	11948-11952	were	_
66-19	11953-11963	restricted	_
66-20	11964-11966	to	_
66-21	11967-11970	the	_
66-22	11971-11979	striatal	_
66-23	11980-11986	voxels	_
66-24	11987-11993	within	_
66-25	11994-11997	the	_
66-26	11998-12005	caudate	_
66-27	12006-12009	and	_
66-28	12010-12017	putamen	_
66-29	12018-12020	as	_
66-30	12021-12028	defined	_
66-31	12029-12031	by	_
66-32	12032-12035	the	_
66-33	12036-12039	AAL	_
66-34	12040-12045	atlas	_
66-35	12046-12047	.	_

67-1	12048-12049	A	_
67-2	12050-12060	voxel-wise	_
67-3	12061-12064	CDT	_
67-4	12065-12067	of	_
67-5	12068-12069	p	_
67-6	12070-12071	<	_
67-7	12072-12076	.001	_
67-8	12077-12080	was	_
67-9	12081-12088	applied	_
67-10	12089-12091	to	_
67-11	12092-12095	the	_
67-12	12096-12108	second-level	_
67-13	12109-12115	t-maps	_
67-14	12116-12117	,	_
67-15	12118-12121	and	_
67-16	12122-12129	minimum	_
67-17	12130-12137	cluster	_
67-18	12138-12144	extent	_
67-19	12145-12148	for	_
67-20	12149-12161	significance	_
67-21	12162-12164	at	_
67-22	12165-12166	a	_
67-23	12167-12170	FWE	_
67-24	12171-12175	rate	_
67-25	12176-12178	of	_
67-26	12179-12180	p	_
67-27	12181-12182	<	_
67-28	12183-12186	.05	_
67-29	12187-12190	was	_
67-30	12191-12201	determined	_
67-31	12202-12204	by	_
67-32	12205-12208	the	_
67-33	12209-12213	FWEc	_
67-34	12214-12227	cluster-level	_
67-35	12228-12238	correction	_
67-36	12239-12242	for	_
67-37	12243-12251	multiple	_
67-38	12252-12262	comparison	_
67-39	12263-12271	function	_
67-40	12272-12283	implemented	_
67-41	12284-12286	in	_
67-42	12287-12292	SPM12	_
67-43	12293-12294	.	_

68-1	12295-12303	Findings	_
68-2	12304-12308	that	_
68-3	12309-12312	did	_
68-4	12313-12316	not	_
68-5	12317-12324	survive	_
68-6	12325-12329	FWEc	_
68-7	12330-12340	correction	_
68-8	12341-12344	are	_
68-9	12345-12353	reported	_
68-10	12354-12356	as	_
68-11	12357-12368	uncorrected	_
68-12	12369-12370	.	_

69-1	12371-12379	Clinical	_
69-2	12380-12390	Correlates	_
69-3	12391-12393	In	_
69-4	12394-12397	the	_
69-5	12398-12400	CU	_
69-6	12401-12406	group	_
69-7	12407-12408	,	_
69-8	12409-12420	correlation	_
69-9	12421-12429	analyses	_
69-10	12430-12434	were	_
69-11	12435-12444	conducted	_
69-12	12445-12447	to	_
69-13	12448-12455	examine	_
69-14	12456-12459	the	_
69-15	12460-12473	relationships	_
69-16	12474-12476	of	_
69-17	12477-12493	conflict-related	_
69-18	12494-12504	activation	_
69-19	12505-12508	and	_
69-20	12509-12521	connectivity	_
69-21	12522-12526	with	_
69-22	12527-12535	cannabis	_
69-23	12536-12539	use	_
69-24	12540-12541	.	_

70-1	12542-12546	Each	_
70-2	12547-12558	participant	_
70-3	12559-12560	’	_
70-4	12561-12562	s	_
70-5	12563-12570	average	_
70-6	12571-12581	activation	_
70-7	12582-12585	and	_
70-8	12586-12598	connectivity	_
70-9	12599-12608	estimates	_
70-10	12609-12613	were	_
70-11	12614-12623	extracted	_
70-12	12624-12628	from	_
70-13	12629-12633	each	_
70-14	12634-12641	cluster	_
70-15	12642-12646	that	_
70-16	12647-12650	was	_
70-17	12651-12661	determined	_
70-18	12662-12664	to	_
70-19	12665-12667	be	_
70-20	12668-12679	significant	_
70-21	12680-12682	in	_
70-22	12683-12686	our	_
70-23	12687-12699	second-level	_
70-24	12700-12705	group	_
70-25	12706-12714	analyses	_
70-26	12715-12716	.	_

71-1	12717-12724	Pearson	_
71-2	12725-12726	’	_
71-3	12727-12728	s	_
71-4	12729-12741	coefficients	_
71-5	12742-12746	were	_
71-6	12747-12751	then	_
71-7	12752-12760	computed	_
71-8	12761-12768	between	_
71-9	12769-12774	these	_
71-10	12775-12784	estimates	_
71-11	12785-12788	and	_
71-12	12789-12792	the	_
71-13	12793-12794	1	_
71-14	12795-12796	)	_
71-15	12797-12800	age	_
71-16	12801-12803	of	_
71-17	12804-12809	first	_
71-18	12810-12817	regular	_
71-19	12818-12826	cannabis	_
71-20	12827-12830	use	_
71-21	12831-12832	,	_
71-22	12833-12834	2	_
71-23	12835-12836	)	_
71-24	12837-12845	duration	_
71-25	12846-12848	of	_
71-26	12849-12852	use	_
71-27	12853-12854	(	_
71-28	12855-12857	in	_
71-29	12858-12863	years	_
71-30	12864-12865	)	_
71-31	12866-12868	,3	_
71-32	12869-12870	)	_
71-33	12871-12875	days	_
71-34	12876-12878	of	_
71-35	12879-12882	use	_
71-36	12883-12885	in	_
71-37	12886-12889	the	_
71-38	12890-12894	past	_
71-39	12895-12897	30	_
71-40	12898-12902	days	_
71-41	12903-12904	,	_
71-42	12905-12908	and	_
71-43	12909-12910	4	_
71-44	12911-12912	)	_
71-45	12913-12917	days	_
71-46	12918-12920	of	_
71-47	12921-12931	abstinence	_
71-48	12932-12937	prior	_
71-49	12938-12940	to	_
71-50	12941-12949	scanning	_
71-51	12950-12951	.	_

72-1	12952-12961	Potential	_
72-2	12962-12973	Confounding	_
72-3	12974-12981	Effects	_
72-4	12982-12984	To	_
72-5	12985-12991	assess	_
72-6	12992-13001	potential	_
72-7	13002-13013	confounding	_
72-8	13014-13021	effects	_
72-9	13022-13024	of	_
72-10	13025-13036	comorbidity	_
72-11	13037-13039	in	_
72-12	13040-13043	the	_
72-13	13044-13046	CU	_
72-14	13047-13052	group	_
72-15	13053-13054	,	_
72-16	13055-13058	I-C	_
72-17	13059-13069	activation	_
72-18	13070-13074	maps	_
72-19	13075-13079	were	_
72-20	13080-13088	compared	_
72-21	13089-13095	across	_
72-22	13096-13102	groups	_
72-23	13103-13105	in	_
72-24	13106-13116	additional	_
72-25	13117-13129	second-level	_
72-26	13130-13140	two-sample	_
72-27	13141-13148	t-tests	_
72-28	13149-13150	(	_
72-29	13151-13155	FWEc	_
72-30	13156-13157	)	_
72-31	13158-13163	after	_
72-32	13164-13173	excluding	_
72-33	13174-13176	CU	_
72-34	13177-13189	participants	_
72-35	13190-13194	with	_
72-36	13195-13203	comorbid	_
72-37	13204-13205	1	_
72-38	13206-13207	)	_
72-39	13208-13239	attention-deficit/hyperactivity	_
72-40	13240-13248	disorder	_
72-41	13249-13250	(	_
72-42	13251-13255	ADHD	_
72-43	13256-13257	)	_
72-44	13258-13259	,	_
72-45	13260-13261	2	_
72-46	13262-13263	)	_
72-47	13264-13269	major	_
72-48	13270-13280	depressive	_
72-49	13281-13289	disorder	_
72-50	13290-13291	(	_
72-51	13292-13295	MDD	_
72-52	13296-13297	)	_
72-53	13298-13299	,	_
72-54	13300-13301	3	_
72-55	13302-13303	)	_
72-56	13304-13311	anxiety	_
72-57	13312-13321	disorders	_
72-58	13322-13323	,	_
72-59	13324-13327	and	_
72-60	13328-13329	4	_
72-61	13330-13331	)	_
72-62	13332-13343	significant	_
72-63	13344-13351	alcohol	_
72-64	13352-13355	use	_
72-65	13356-13357	.	_

73-1	13358-13360	We	_
73-2	13361-13373	additionally	_
73-3	13374-13382	explored	_
73-4	13383-13386	and	_
73-5	13387-13397	controlled	_
73-6	13398-13401	for	_
73-7	13402-13405	the	_
73-8	13406-13413	effects	_
73-9	13414-13416	of	_
73-10	13417-13419	IQ	_
73-11	13420-13423	and	_
73-12	13424-13427	SES	_
73-13	13428-13430	on	_
73-14	13431-13434	our	_
73-15	13435-13440	group	_
73-16	13441-13452	differences	_
73-17	13453-13455	in	_
73-18	13456-13472	conflict-related	_
73-19	13473-13483	activation	_
73-20	13484-13487	and	_
73-21	13488-13500	connectivity	_
73-22	13501-13503	by	_
73-23	13504-13514	conducting	_
73-24	13515-13524	ROI-based	_
73-25	13525-13533	analyses	_
73-26	13534-13539	using	_
73-27	13540-13543	the	_
73-28	13544-13553	extracted	_
73-29	13554-13563	parameter	_
73-30	13564-13573	estimates	_
73-31	13574-13578	from	_
73-32	13579-13583	each	_
73-33	13584-13595	significant	_
73-34	13596-13603	cluster	_
73-35	13604-13612	detected	_
73-36	13613-13615	in	_
73-37	13616-13619	our	_
73-38	13620-13624	main	_
73-39	13625-13633	analyses	_
73-40	13634-13635	.	_

